Show simple item record

dc.contributor.authorHanna, David B
dc.contributor.authorJung, Molly
dc.contributor.authorXue, Xiaonan
dc.contributor.authorAnastos, Kathryn
dc.contributor.authorCocohoba, Jennifer M
dc.contributor.authorCohen, Mardge H
dc.contributor.authorGolub, Elizabeth T
dc.contributor.authorHessol, Nancy A
dc.contributor.authorLevine, Alexandra M
dc.contributor.authorWilson, Tracey E
dc.contributor.authorYoung, Mary A
dc.contributor.authorKaplan, Robert C
dc.date.accessioned2023-09-27T15:44:11Z
dc.date.available2023-09-27T15:44:11Z
dc.identifier.citationHanna DB, Jung M, Xue X, Anastos K, Cocohoba JM, Cohen MH, Golub ET, Hessol NA, Levine AM, Wilson TE, Young MA, Kaplan RC. Trends in Nonlipid Cardiovascular Disease Risk Factor Management in the Women's Interagency HIV Study and Association with Adherence to Antiretroviral Therapy. AIDS Patient Care STDS. 2016 Oct;30(10):445-454. doi: 10.1089/apc.2016.0143. PMID: 27749112; PMCID: PMC5069716.en_US
dc.identifier.eissn1557-7449
dc.identifier.pmid27749112
dc.identifier.urihttp://hdl.handle.net/20.500.12648/13019
dc.description.abstractCardiovascular disease (CVD) is increasingly common among women with HIV, but literature on nonlipid CVD risk factor management is lacking. We examined semiannual trends from 2006 to 2014 in hypertension treatment and control (blood pressure <140/90 mmHg), diabetes treatment and control (fasting glucose <130 mg/dL), and smoking quit rates in the Women's Interagency HIV Study. Unadjusted and adjusted Poisson regression models tested time trends and differences between HIV+ and HIV- women. Among antiretroviral therapy (ART) users, we examined the association of ART adherence and virologic suppression with each outcome. We evaluated 1636 HIV+ and 683 HIV- women, with a hypertension prevalence of 40% and 38%, respectively; diabetes prevalence of 21% and 22%; and smoking prevalence of 37% and 48%. Hypertension treatment was higher among HIV+ than HIV- women (77% vs. 67%, p < 0.001) and increased over time with no difference in trend by HIV status. Hypertension control was greater among HIV+ women (56% vs. 43%, p < 0.001) and increased over time among HIV+ but not HIV- women. Diabetes treatment was similar among HIV+ and HIV- women (48% vs. 49%) and increased over time in both groups. Diabetes control was greater among HIV+ women (73% vs. 64%, p = 0.03) and did not change over time. The percent of recent smokers who reported no longer smoking was similar between HIV+ and HIV- women (10% vs. 9%), with no differences over time. Virologic suppression was significantly associated with increased hypertension treatment and greater control. HIV+ women have better control of hypertension and diabetes than HIV- women, but many are still not at target levels.
dc.language.isoenen_US
dc.relation.urlhttps://www.liebertpub.com/doi/10.1089/apc.2016.0143en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHIV-1 viral loaden_US
dc.subjectantiretroviral therapyen_US
dc.subjectcardiovascular diseaseen_US
dc.subjectdiabetes mellitusen_US
dc.subjecthypertensionen_US
dc.subjectsmokingen_US
dc.titleTrends in Nonlipid Cardiovascular Disease Risk Factor Management in the Women's Interagency HIV Study and Association with Adherence to Antiretroviral Therapy.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAIDS patient care and STDsen_US
dc.source.volume30
dc.source.issue10
dc.source.beginpage445
dc.source.endpage454
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-09-27T15:44:12Z
html.description.abstractCardiovascular disease (CVD) is increasingly common among women with HIV, but literature on nonlipid CVD risk factor management is lacking. We examined semiannual trends from 2006 to 2014 in hypertension treatment and control (blood pressure <140/90 mmHg), diabetes treatment and control (fasting glucose <130 mg/dL), and smoking quit rates in the Women's Interagency HIV Study. Unadjusted and adjusted Poisson regression models tested time trends and differences between HIV+ and HIV- women. Among antiretroviral therapy (ART) users, we examined the association of ART adherence and virologic suppression with each outcome. We evaluated 1636 HIV+ and 683 HIV- women, with a hypertension prevalence of 40% and 38%, respectively; diabetes prevalence of 21% and 22%; and smoking prevalence of 37% and 48%. Hypertension treatment was higher among HIV+ than HIV- women (77% vs. 67%, p < 0.001) and increased over time with no difference in trend by HIV status. Hypertension control was greater among HIV+ women (56% vs. 43%, p < 0.001) and increased over time among HIV+ but not HIV- women. Diabetes treatment was similar among HIV+ and HIV- women (48% vs. 49%) and increased over time in both groups. Diabetes control was greater among HIV+ women (73% vs. 64%, p = 0.03) and did not change over time. The percent of recent smokers who reported no longer smoking was similar between HIV+ and HIV- women (10% vs. 9%), with no differences over time. Virologic suppression was significantly associated with increased hypertension treatment and greater control. HIV+ women have better control of hypertension and diabetes than HIV- women, but many are still not at target levels.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentCommunity Health Sciencesen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAIDS patient care and STDs
dc.identifier.issue10en_US


Files in this item

Thumbnail
Name:
apc.2016.0143.pdf
Size:
334.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International